Yawn Barbara P, Kaplan Alan
Department of Research, Olmsted Medical Center, Rochester, Minnesota 55904, USA.
Prim Care Respir J. 2008 Dec;17(4):199-205. doi: 10.3132/pcrj.2008.00021.
There has been increased awareness and recognition of COPD in both developed and developing nations. As people with COPD are identified and treated before they reach end-stage lung disease, the multiple morbidities associated with COPD have been recognised. These morbidities affect many areas of the body and currently are often treated with numerous different drugs. This poly-pharmacy, and the need for therapy by multiple organ-specific specialists, is not optimal and often not feasible for patients with COPD. New information on many of the common multiple morbidities suggests that it may be possible to explain--and in the future control or treat--these multiple morbidities, by addressing one common trigger and a common final pathway of inflammation. This review outlines some of the reasons why it is time to consider a 'whole body' approach to COPD, rather than clinicians continuing to address the lungs first and then each additional organ one at a time.
在发达国家和发展中国家，慢性阻塞性肺疾病（COPD）的知晓度和认知度都有所提高。随着COPD患者在发展到终末期肺病之前得到识别和治疗，与COPD相关的多种合并症已得到认识。这些合并症会影响身体的许多部位，目前常常使用多种不同药物进行治疗。这种联合用药，以及需要多个器官专科医生进行治疗的情况，对于COPD患者来说并非最佳选择，而且往往不可行。关于许多常见合并症的新信息表明，通过解决一个共同的触发因素和炎症的共同最终途径，有可能解释——并在未来控制或治疗——这些合并症。这篇综述概述了为何是时候考虑对COPD采取“全身”治疗方法的一些原因，而不是临床医生继续首先关注肺部，然后逐个处理其他器官的问题。
